Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Trial Profile

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs MIV-818 (Primary)
  • Indications Cholangiocarcinoma; Liver cancer; Liver metastases
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Medivir AB
  • Most Recent Events

    • 14 Dec 2018 According to a Medivir AB media release, three patients have already been included in an ongoing phase I study and results from the the phase Ia part of this study to be available during Q2 2019.
    • 12 Oct 2018 New trial record
    • 01 Oct 2018 According to a Medivir AB media release, the first patient has been enrolled and dosed in this trial. The regulatory application to conduct the study was first reviewed and approved by the United Kingdom Medicinal and Healthcare Products Regulatory Agency (MHRA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top